歐洲的冠狀動脈支架市場

Abstract

Budgetary Restraints Affect Growth of Drug Eluting Stents

Drug eluting stents (DES) represent one of the most exciting discoveries made in the field of interventional cardiology. Unique design, pharmacological agents and the drug delivery vehicle of these revolutionary medical devices offer significant advantages over bare metal stents (BMS). However, with the average prices of BMS ranging between $400-800, which is almost half that of DES, these stents score over DES in terms of cost. This is a strong influencing factor for governments to choose BMS over DES, despite the many advantages of the latter. Faced with rising healthcare costs, governments are compelled to curtail hospital budgets. Restricted purchasing power of hospitals combined with a lack of reimbursements has limited the use of DES in Europe, with more than 50 per cent of clinical procedures continuing to use BMS. Increased uptake of DES calls for ongoing clinical trials to highlight the benefits of these stents, especially for certain indications. Manufacturers must also strive to reduce prices of DES; this could help drive sales volumes and ensure repeat purchases.

This Frost & Sullivan research service provides an in-depth analysis of the European coronary stents market, evaluating its business potential in seven key regions of Europe. It discusses the major challenges, drivers and restraints affecting the market and provides strategic recommendations to overcome these challenges. The study includes a detailed assessment of the existing competitive structure and the current market shares of key participants.

Need to Produce Stents that Meet Safety Standards

The safety of the stents currently in the market is a key challenge facing manufacturers. With healthcare providers under pressure to improve levels of service and meet patients' demands, government officials have started imposing strict safety standards for medical devices and periodical safety reviews by governments have become the norm in the region.

Coronary stents are used in highly delicate cardiac procedures and therefore, it is critical that they do not cause any additional complications to the patient. However, the biocompatibility and deliverability of DES are crucial in ensuring the efficacy of the procedure. "A major concern in this respect is the thrombogenocity of these devices," remarks the analyst of this research service. "Many believe that the polymeter in DES, which releases the drug over time, plays a pivotal role in the appearance of late thrombosis; however, this is an area which needs to be examined further."

Drug Therapy Provides Strong Competition to Coronary Stents

While coronary stents have successfully addressed complications such as stenosis and occlusion, problems such as restenosis and thrombosis are sources of much concern in the interventional cardiology industry. Stents manufacturers face stiff competition from pharmaceutical companies that have developed drugs, which are effectively addressing such problems. "Pharmacological agents have the ability to reduce stenosis, prevent or dissolve thrombi and dilate arteries at various developmental stages," notes the analyst. "Drug treatments are significantly more cost-effective than surgical procedures and therefore pose a strong challenge to the development of the coronary stents market."

Drug companies also have well-developed distribution channels and have gained the loyalty of clinicians. Manufacturers of medical devices must attempt to change such loyalties by raising awareness of the advantages of minimally invasive procedures compared to existing alternatives such as drug therapy.

Table of Contents

• 1. Executive Summary
  • 1. Executive Summary of the European Coronary Stents Market
    • 1. Executive Summary
• 2. Glossary of Terms
  • 1. Glossary
    • 1. Glossary
• 3. Industry Challenges
  • 1. Identification of Strategic Challenges Affecting the European Coronary Stents Market
    • 1. Challenges of the European Coronary Stents Market
• 4. Market Engineering Research for the European Coronary Stents Market
  • 1. Market Overview
    • 1. Introduction
  • 2. Market Segmentation
    • 1. Definition
    • 2. Indications and Application of Coronary Stents
    • 3. Coronary Stent Segmentation
  • 3. Market Engineering Measurements
    • 1. Coronary Stents Market Engineering Measurements for Western Europe
  • 4. Market Drivers
    • 1. Drivers
      • a. Aging Population Drives Sales for Coronary Stents
      • b. Minimal Invasive Surgery Driving Demand for Stenting Procedures
      • c. Affordable Bare Metal Stents Drives the Growth for Stenting Procedures
      • d. Base Metal Stents (BES) Deployment Provide Greater Safety For Particular Cardiovascular Indications
      • e. Drug Eluting Stents (DES) will Expand the Coronary Market
      • f. Increase in Number of Clinical Trials Driving Demand for Drug Eluting Stents (DES)
      • g. Lack of European Guidelines Driving Growth for Stenting in Europe
      • h. Increase of Patient Awareness Drives Uptake for Stenting Procedures
  • 5. Market Restraints
    • 1. Restraints
      • a. Limited Drug Eluting Stents (DES) Data Impacting Growth
      • b. Patent Laws Restricting Product Innovation for Stents
      • c. Alternative Treatment Posing a Threat to the Coronary Stents Market
      • d. Consolidation of the Market Creates Barriers to Entry for Small Manufacturers Restricting Growth
  • 6. Revenue Forecast for the Coronary Stents Market
    • 1. Methodology
    • 2. Forecasts
  • 7. Geographical Trends
    • 1. Analysis of Geographical Trends
  • 8. Market Size for the Coronary Stents Market
    • 1. Market Shares
• 5. Market Engineering Research for the Benelux Coronary Stents Market
  • 1. Introduction
    • 1. Introduction
  • 2. Market Drivers and Restraints
    • 1. Market Drivers
    • 2. Market Restraints
• 6. Market Engineering Research for the French Coronary Stents Market
  • 1. Introduction
    • 1. Introduction
  • 2. Market Drivers and Restraints
    • 1. Market Drivers
    • 2. Market Restraints
• 7. Market Engineering Research for the German Coronary Stents Market
  • 1. Introduction
    • 1. Introduction
  • 2. Germany's National Health Service
    • 1. BVMed
  • 3. Market Drivers and Restraints
    • 1. Market Drivers
    • 2. Market Restraints
• 8. Market Engineering Research for the Italian Coronary Stents Market
  • 1. Introduction
    • 1. Introduction to the Italian Healthcare Market
  • 2. Italian National Health System
    • 1. Diagnostic Related Groups (DRGs)
  • 3. Market Drivers and Restraints
    • 1. Market Drivers
    • 2. Market Restraints
• 9. Market Engineering Research for the Scandinavian Coronary Stents Market
  • 1. Introduction
    • 1. Introduction to the Scandinavian Healthcare Market
  • 2. Market Drivers and Restraints
    • 1. Market Drivers
    • 2. Market Restraints
• 10. Market Engineering Research for the Spanish Coronary Stents Market
  • 1. Introduction
    • 1. Introduction to the Spanish Healthcare Market
  • 2. Market Drivers and Restraints
    • 1. Market Drivers
    • 2. Market Restraints
• 11. Market Engineering Research for the United Kingdom Coronary Stents Market
  • 1. Introduction
    • 1. Introduction
    • 2. National Institute of Clinical Excellence
  • 2. Market Drivers and Restraints
    • 1. Market Drivers
    • 2. Market Restraints
• 12. Market Engineering Strategy
  • 1. Strategies
    • 1. Definition of Market Engineering Strategy
    • 2. Market Engineering Strategic Recommendations
• 13. Frost & Sullivan Awards for the European Coronary Stents
  • 1. Frost & Sullivan Awards for the European Coronary Stent Market
    • 1. Frost & Sullivan Awards
    • 2. Frost & Sullivan 2005 Product Quality Leadership Award
    • 3. Frost & Sullivan 2005 Market Leadership Award
    • 4. Frost & Sullivan 2005 Competitive Strategy Leadership Award
• 14. Database of Key Industry Participants
  • 1. Key Industry Participants
    • 1. Participants
• 15. Decision Support Database
  • 1. Demographics
    • 1. Female Population 65 and Above
    • 2. Male Population 65 and Above
    • 3. Population 65 and Above
  • 2. Healthcare Infrastructure
    • 1. Number of Hospitals
    • 2. Number of Specialized Medical Practitioners
    • 3. Number of Hospital Beds